Drug intelligence / Profile preview

PYTX-002

Development stage: Preclinical
Lead developer: Papyrus Therapeutics
Modality: Gene Therapies

Overview

PYTX-002 is a gene replacement therapy developed by Papyrus Therapeutics Inc. It is based on the OPCML tumor suppressor and is designed to condition the tumor microenvironment. The drug aims to enhance the activation and efficacy of CAR-T cell therapy, particularly in the challenging treatment of solid tumors.

Targets

AXL (AXL receptor tyrosine kinase)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EPHA2 (Ephrin type-A receptor 2)FGFR3 (Fibroblast growth factor receptor 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)OPCML (Opioid binding protein/cell adhesion molecule-like)FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on PYTX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYTX-002.

Explore the full profile